Fujirebio Europe launches the Lumipulse® G Aldosterone and Renin assays for fully automated quantitative determination of aldosterone and active renin

Product news

Gent, Belgium: July 1st, 2020 - Fujirebio Europe announces the release of the Lumipulse G Aldosterone and Renin assays for the fully automated quantitative determination of aldosterone and active renin, respectively, in human plasma, serum and additionally for aldosterone in urine. The Lumipulse G Aldosterone and Lumipulse G Renin assays are based on a specific two-step sandwich immunoassay method for the LUMIPULSE G System and use fully automated unique cartridge CLEIA technology.

"We are happy to finally be able to offer clinicians and laboratories a reliable and easy-to-use hypertension patient management solution," said Christiaan De Wilde, CEO of Fujirebio Europe. "These two new automated assays for measurement of renin and aldosterone run using the well-established quality of our LUMIPULSE G System, and we are convinced they will offer great help for clinicians in the diagnosis and treatment of primary aldosteronism in hypertension patients."

About primary aldosteronism

An estimated 1.13 billion people worldwide are suffering from hypertension with an overall prevalence of 30-45% that strongly correlates with age1. Most cases have no clear etiology and are classified as having primary or essential hypertension. Five to 15% percent of hypertensive patients however suffer from primary aldosteronism, which is caused by an excess production of aldosterone by the adrenal gland independent of the renin-angiotensin system by which it is regulated under physiological conditions.

The guidelines for the management of arterial hypertension issued by the European Society of Cardiology / Hypertension recommend screening for primary aldosteronism by analyzing the renin, aldosterone and potassium concentration2. Primary aldosteronism is mostly asymptomatic and characterized by a high resistance to pharmacological treatments, while patients generally show a higher risk of cardiovascular morbidity and mortality compared to other hypertensive patients with the same degree of blood pressure elevation3.

About Fujirebio

Fujirebio is a global leader in the field of high-quality in vitro diagnostics (IVD) testing. It has more than 50 years’ accumulated experience in the conception, development, production and worldwide commercialization of robust IVD products.

Founded in 1950 in Tokyo, Japan, Fujirebio has over the years concluded a number of successful acquisitions of best-in-class IVD companies. Examples include Centocor Diagnostics in 1998, CanAg Diagnostics in 2006 and Innogenetics in 2010. Today, Fujirebio’s global presence includes offices in the United States, Latin America, Europe and Asia as well as a vast international distribution network.

Fujirebio has a strong and long-lasting tradition of collaborating with experts in the worldwide clinical community in the development of high-quality routine and truly novel biomarkers that cover a variety of disease states. Its IVD product lines span the range from specialized manual and automated testing to fully automated routine clinical laboratory testing solutions.

Fujirebio is a wholly-owned subsidiary of H.U. Group Holdings, Inc. (formerly known as Miraca Holdings Inc - listed on the Tokyo Stock Exchange – TYO: 4544) and employs more than 1.200 people in Asia, Europe and America.



  1. NCD Risk Factor Collaboration, Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants. Lancet 2017; 389:37-55
  2. Williams et al., 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens 2018; 36(10): 1953-2041
  3. Rossi et al., Long-term Control of Arterial Hypertension and Regression of Left Ventricular Hypertrophy With Treatment of Primary Aldosteronism. Hypertension 2013; 62(1):62-9